Next Article in Journal
Resolution of Severe Oncogenic Hypophosphatemic Osteomalacia after Resection of a Deeply Located Soft-Tissue Tumour
Previous Article in Journal
Response to 5-Fluorouracil in Metastatic Extramammary Paget Disease of the Scrotum Presenting as Pancytopenia and Back Pain
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 16
Issue 5
10.3747/co.v16i5.395
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Efficacy of Third-Line Therapy Using Bevacizumab in a Patient with Metastatic Colorectal Cancer

by
J. Gaulin
1,
R. Kotb
1,2,*,
E. Turcotte
3,
G. Berard
4,
B. Sawan
5,
G. Schmutz
6 and
P. Beauregard
1
1
Departments of Hematology and Oncology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada
2
Division of Hematology, Sherbrooke University, 3001–12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
3
Departments of Nuclear Medicine, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada
4
Departments of Clinical Pharmacy, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada
5
Departments of Pathology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada
6
Departments of Radiology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2009, 16(5), 84-86; https://doi.org/10.3747/co.v16i5.395
Submission received: 4 June 2009 / Revised: 8 July 2009 / Accepted: 12 August 2009 / Published: 1 September 2009

Abstract

Bevacizumab is currently approved in association with first- and second-line 5-fluorouracil–based chemotherapy regimens for patients with metastatic colorectal cancer. Few data about the usefulness of bevacizumab in third-line settings are available. We describe a patient refractory to folfiri and folfox chemotherapy regimens who showed a dramatic and durable response to bevacizumab and folfiri. We also review and discuss the available literature.
Keywords: colorectal cancer; bevacizumab; third-line therapy colorectal cancer; bevacizumab; third-line therapy

Share and Cite

MDPI and ACS Style

Gaulin, J.; Kotb, R.; Turcotte, E.; Berard, G.; Sawan, B.; Schmutz, G.; Beauregard, P. Efficacy of Third-Line Therapy Using Bevacizumab in a Patient with Metastatic Colorectal Cancer. Curr. Oncol. 2009, 16, 84-86. https://doi.org/10.3747/co.v16i5.395

AMA Style

Gaulin J, Kotb R, Turcotte E, Berard G, Sawan B, Schmutz G, Beauregard P. Efficacy of Third-Line Therapy Using Bevacizumab in a Patient with Metastatic Colorectal Cancer. Current Oncology. 2009; 16(5):84-86. https://doi.org/10.3747/co.v16i5.395

Chicago/Turabian Style

Gaulin, J., R. Kotb, E. Turcotte, G. Berard, B. Sawan, G. Schmutz, and P. Beauregard. 2009. "Efficacy of Third-Line Therapy Using Bevacizumab in a Patient with Metastatic Colorectal Cancer" Current Oncology 16, no. 5: 84-86. https://doi.org/10.3747/co.v16i5.395

Article Metrics

Back to TopTop